Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease

Microbiology and Molecular Biology Reviews

Volumn 77, Issue 2, 2013, Pages 234-252

  McNeil, Lisa K ^a   Zagursky, Robert J ^a,b   Lin, Shuo L ^a   Murphy, Ellen ^a   Zlotnick, Gary W ^a   Hoiseth, Susan K ^a   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a  

^a Pfizervaccine Research   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; FACTOR H BINDING PROTEIN; MENINGITIS VACCINE; UNCLASSIFIED DRUG;

AGED; BACTERIAL CELL; BACTERIAL VIRULENCE; CELL SURFACE; COMPUTER MODEL; HUMAN; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PROTEIN CONFORMATION; VIRULENCE;

EID: 84878250643     PISSN: 10922172     EISSN: 10985557     Source Type: Journal    
DOI: 10.1128/MMBR.00056-12     Document Type: Review

References (146)

1. Stephens DS. 2007. Conquering the meningococcus. FEMS Microbiol. Rev. 31:3-14. (Pubitemid 46058815)
2. Wilder-Smith A. 2009. Meningococcal vaccines: a neglected topic in travel medicine? Expert Rev. Vaccines 8:1343-1350.
3. Goldschneider I, Gotschlich EC, Artenstein MS. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
4. Caugant DA, Maiden MCJ. 2009. Meningococcal carriage and disease - population biology and evolution. Vaccine 27:B64-B70.
5. Claus H, Maiden MC, Wilson DJ, McCarthy ND, Jolley KA, Urwin R, Hessler F, Frosch M, Vogel U. 2005. Genetic analysis of meningococci carried by children and young adults. J. Infect. Dis. 191:1263-1271.
6. Stephens DS. 1999. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 353:941-942. (Pubitemid 29132597)
7. Healy CM, Baker CJ. 2005. The future of meningococcal vaccines. Pediatr. Infect. Dis. J. 24:175-176. (Pubitemid 40250778)
8. Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM. 2012. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum. Vaccin. Immunother. 8:866-872.
9. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. 2001. Meningococcal disease. N. Engl. J. Med. 344:1378-1388.
10. Finne J, Leinonen M, Makela PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357. (Pubitemid 13028927)
11. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. 2009. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27:B3-B12.
12. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, Berman SL, Lowenthal JP. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514-521.
13. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. 2004. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22:1087-1096. (Pubitemid 38296650)
14. Tappero JW, Lagos R, Maldonado Ballesteros A, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, Nokleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527. (Pubitemid 29200936)
15. Cartwright K, Morris R, Rumke H, Fox A, Borrow R, Begg N, Richmond P, Poolman J. 1999. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17:2612-2619. (Pubitemid 29314456)
16. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510. (Pubitemid 43939163)
17. Schneider MC, Exley RM, Chan H, Feavers I, Kang Y-H, Sim RB, Tang CM. 2006. Functional significance of factor H binding to Neisseria meningitidis. J. Immunol. 176:7566-7575. (Pubitemid 43849060)
18. Bernfield L, Fletcher LD, Howell A, Farley JE, Zagursky R, Knauf M, Zlotnick G. 2002. Identification of a novel vaccine candidate for group B Neisseria meningitidis, p 116. Proc. 13th Int. Pathog. Neisseria Conf., Oslo, Norway.
19. Farley J, Fletcher L, Bernfield L, Howell A, Knauf M, Weise P, Xie X, Zhang Y. 2002. Characterization, cloning and expression of different subfamilies of the ORF 2086 gene from Neisseria meningitidis, p 124. Proc. 13th Int. Pathog. Neisseria Conf., Oslo, Norway.
20. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, Serruto D, Litt D, Kroll S, Welsch JA, Granoff DM, Rappuoli R, Pizza M. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799. (Pubitemid 36350873)
21. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, Xie X, Zagursky R, Zhang Y, Zlotnick GW. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100. (Pubitemid 38419922)
22. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839. (Pubitemid 44148381)
23. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086-6093.
24. Frasch CE, Borrow R, Donnelly J. 2009. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27:B112-B116.
25. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter JC, Moxon ER, Grandi G, Rappuoli R. 2000. Identification of vaccine candidates against serogroup B meningococcus by wholegenome sequencing. Science 287:1816-1820. (Pubitemid 30143965)
26. Wu HC. 1996. Biosynthesis of lipoproteins, p 1005-1014. In Neidhardt FC, et al. (ed), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed, vol 1. ASM Press, Washington, DC.
27. Litt D, Savino S, Beddek A, Comanducci M, Sandiford C, Stevens J, Levin M, Ison C, Pizza M, Rappuoli R, Kroll JS. 2004. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J. Infect. Dis. 190:1488-1497. (Pubitemid 39332190)
28. Schwarz R, Seibel PN, Rahmann S, Schoen C, Huenerberg M, Muller-Reible C, Dandekar T, Karchin R, Schultz J, Muller T. 2009. Detecting species-site dependencies in large multiple sequence alignments. Nucleic Acids Res. 37:5959-5968.
29. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379-389.
30. Beernink PT, Granoff DM. 2009. The modular architecture of meningococcal factor H-binding protein. Microbiology 155:2873-2883.
31. Pajon R, Beernink PT, Harrison LH, Granoff DM. 2010. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 28:2122-2129.
32. Brehony C, Wilson DJ, Maiden MCJ. 2009. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155:4155-4169.
33. Anderson A, Hoiseth S, Murphy E, Andrew L, McNeil L, Abad R, Vazquez J, Vogel U, Frosch M, Jansen K. 2009. Epidemiology of the serogroup B N. meningitidis (MNB) factor H binding protein and implications for vaccine development, p P505. Abstr. 27th Annu. Meet. Eur. Soc. Paediatr. Infect. Dis., Brussels, Belgium.
34. Jacobsson S, Hedberg ST, Molling P, Unemo M, Comanducci M, Rappuoli R, Olcen P. 2009. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 27:1579-1584.
35. de Filippis I, de Lemos AP, Hostetler JB, Wollenberg K, Sacchi CT, Harrison LH, Bash MC, Prevots DR. 2012. Molecular epidemiology of Neisseria meningitidis serogroup B in Brazil. PLoS One 7:e33016. doi:10.1371/journal.pone. 0033016.
36. Mothibeli KM, du Plessis M, von Gottberg A, Murphy E, Hoiseth SK, Zlotnick G, Klugman KP. 2011. Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine 29:2187-2192.
37. Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseth SK, Jansen KU, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LW. 2011. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 29:4739-4744.
38. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. 2009. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J. Infect. Dis. 199:1360-1368.
39. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. 2011. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl. Trop. Dis. 5:e1302. doi:10.1371/journal.pntd.0001302.
40. Christensen H, May M, Bowen L, Hickman M, Trotter CL. 2010. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10:853-861.
41. Marsh JW, Shutt KA, Pajon R, Tulenko MM, Liu S, Hollick RA, Kiehlbauch JA, Clark TA, Stephens DS, Arnold KE, Myers RA, Mayer LW, Harrison LH. 2011. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. Vaccine 29:6049-6058.
42. Harris SL, Zhu D, Murphy E, McNeil LK, Wang X, Mayer LW, Harrison LH, Jansen KU, Anderson AS. 2011. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C. Dis. Hum. Vaccin. 7(Suppl.):68-74.
43. Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, Granoff DM. 2011. Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect. Immun. 80:643-650.
44. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM. 2011. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin. Vaccine Immunol. 18:1002-1014.
45. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6:e1001027. doi:10.1371/journal.ppat.1001027.
46. McNeil LK, Murphy E, Zhao X-J, Guttmann S, Harris SL, Scott AA, Tan C, Mack M, DaSilva I, Alexander K, Mason K, Jiang H-Q, Zhu D, Mininni TL, Zlotnick GW, Hoiseth SK, Jones TR, Pride MW, Jansen KU, Anderson AS. 2009. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27:3417-3421.
47. Mascioni A, Jacob J, Moy F, Dilts D, Fink P, Malakian K, Sigethy S, Wen Y, Novikova E, Zlotnick GW, Tsao DH. 2009. Backbone and side-chain assignment of the lipidated and non-lipidated forms of the meningococcal outer membrane protein LP2086. Biomol. NMR Assign. 3:111-113.
48. Mascioni A, Bentley BE, Camarda R, Dilts DA, Fink P, Gusarova V, Hoiseth SK, Jacob J, Lin SL, Malakian K, McNeil LK, Mininni T, Moy F, Murphy E, Novikova E, Sigethy S, Wen Y, Zlotnick GW, Tsao DHH. 2009. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J. Biol. Chem. 284:8738-8746.
49. Mascioni A, Novikova E, Bentley BE, McNeil LK, Murphy E, Camarda R, Lin S, Ddilts Fink P, Mininni TL, Hoiseth S, Tsao D, Zlotnick GW. 2008. Determination of the domain and solution structure of rLP2086, a meningococcal vaccine candidate and human factor H binding protein, p O61. Proc. 16th Int. Pathog. Neisseria Conf., Rotterdam, The Netherlands.
50. Cantini F, Veggi D, Dragonetti S, Savino S, Scarselli M, Romagnoli G, Pizza M, Banci L, Rappuoli R. 2009. Solution structure of the factor H-binding protein, a survival factor and protective antigen of Neisseria meningitidis. J. Biol. Chem. 284:9022-9026.
51. Cendron L, Veggi D, Girardi E, Zanotti G. 2011. Structure of the uncomplexed Neisseria meningitidis factor H-binding protein fHbp (rLP2086). Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 67:531-535.
52. Schneider MC, Prosser BE, Caesar JJE, Kugelberg E, Li S, Zhang Q, Quoraishi S, Lovett JE, Deane JE, Sim RB, Roversi P, Johnson S, Tang CM, Lea SM. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890-893.
53. Scarselli M, Aricò B, Brunelli B, Savino S, Di Marcello F, Palumbo E, Veggi D, Ciucchi L, Cartocci E, Bottomley MJ, Malito E, Lo Surdo P, Comanducci M, Giuliani MM, Cantini F, Dragonetti S, Colaprico A, Doro F, Giannetti P, Pallaoro M, Brogioni B, Tontini M, Hilleringmann M, Nardi-Dei V, Banci L, Pizza M, Rappuoli R. 2011. Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 3:91ra62. doi:10.1126/scitranslmed.3002234.
54. Emonts M, Hazelzet JA, de Groot R, Hermans PWM. 2003. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect. Dis. 3:565-577. (Pubitemid 37064536)
55. Lo H, Tang CM, Exley RM. 2009. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect. Dis. 9:418-427.
56. Wright V, Hibberd M, Levin M. 2009. Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes. Vaccine 27:B90-B102.
57. Haralambous E, Dolly SO, Hibberd ML, Litt DJ, Udalova IA, O'Dwyer C, Langford PR, Simon Kroll J, Levin M. 2006. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand. J. Infect. Dis. 38:764-771. (Pubitemid 44304965)
58. Pangburn MK. 2000. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacol. 49:149-157. (Pubitemid 30445226)
59. Lambris JD, Ricklin D, Geisbrecht BV. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6:132-142.
60. Ram S, McQuillen DP, Gulati S, Elkins C, Pangburn MK, Rice PA. 1998. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J. Exp. Med. 188:671-680. (Pubitemid 28387930)
61. Shaughnessy J, Lewis LA, Jarva H, Ram S. 2009. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect. Immun. 77:2094-2103.
62. Welsch JA, Ram S. 2008. Factor H and neisserial pathogenesis. Vaccine 26(Suppl. 8):I40-I45.
63. Kraiczy P, Wurzner R. 2006. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol. Immunol. 43 :31-44. (Pubitemid 41024919)
64. Pio R, Elsassr TH, Martinez A, Cuttitta F. 2002. Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma. Microsc. Res. Tech. 57:23-27. (Pubitemid 34242541)
65. Zipfel PF. 2001. Complement factor H: physiology and pathophysiology. Semin. Thromb. Hemost. 27:191-199. (Pubitemid 32550160)
66. DiScipio RG. 1992. Ultrastructures and interactions of complement factors H and I. J. Immunol. 149:2592-2599.
67. Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. 2004. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 41:355-367.
68. Pangburn MK, Atkinson MA, Meri S. 1991. Localization of the heparin-binding site on complement factor H. J. Biol. Chem. 266:16847-16853. (Pubitemid 21907877)
69. Kazatchkine MD, Fearon DT, Austen KF. 1979. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1H for cell-bound C3b. J. Immunol. 122:75-81. (Pubitemid 9078522)
70. Davila S, Wright VJ, Khor CC, Sim KS, Binder A, Breunis WB, Inwald D, Nadel S, Betts H, Carrol ED, de Groot R, Hermans PW, Hazelzet J, Emonts M, Lim CC, Kuijpers TW, Martinon-Torres F, Salas A, Zenz W, Levin M, Hibberd ML. 2010. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 42:772-776.
71. Dunphy KY, Beernink PT, Brogioni B, Granoff DM. 2011. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect. Immun. 79:353-359.
72. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, Muzzi A, DiMarcello F, Marchi S, van der Ende A, Arico B, Savino S, Scarselli M, Comanducci M, Rappuoli R, Giuliani MM, Pizza M. 2011. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect. Immun. 79:970-981.
73. Seib KL, Oriente F, Adu-Bobie J, Montanari P, Ferlicca F, Giuliani MM, Rappuoli R, Pizza M, Delany I. 2010. Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine 28:2416-2427.
74. Giuntini S, Reason DC, Granoff DM. 2011. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factorHbinding. Infect. Immun. 79:3751-3759.
75. McNeil LK, Zlotnick GW, Zhao X, Anderson AS, Jansen KU. 2010. Anti-fHBP antibodies elicited after immunization with a recombinant fHBP vaccine candidate (rLP2086) can displace human factorHfrom the surface of serogroup B meningococci, p 94. Proc. 18th Int. Pathog. Neisseria Conf., Banff, Canada.
76. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186:3606-3614.
77. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, Oster P, Miller E, Pollard AJ. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51:1127-1137.
78. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ. 2012. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307:573-582.
79. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. 2011. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin. Vaccine Immunol. 18:483-486.
80. Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garces-Sanchez M, Martinon-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL. 2012. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 12:597-607.
81. Richmond PC, Nissen MD, Marshall HS, Lambert SB, Roberton D, Gruber WC, Jones TR, Arora A. 2012. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 30:6163-6174.
82. Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, Dull PM. 2012. Imunogenicity and tolerability of a mulicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 379:617-624.
83. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29:e71-79.
84. Granoff DM, Welsch JA, Ram S. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764-769.
85. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. 2001. Importance of complement source in measuring meningococcal bactericidal titers. Clin. Diagn. Lab. Immunol. 8:616-623. (Pubitemid 32428891)
86. Zollinger WD, Mandrell RE. 1983. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:257-264. (Pubitemid 13163064)
87. Snyder LAS, Butcher SA, Saunders NJ. 2001. Comparative whole-genome analyses reveal over 100 putative phase-variable genes in the pathogenic Neisseria spp. Microbiology 147:2321-2332. (Pubitemid 32785512)
88. Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Arico B, Capecchi B, Giuliani MM, Masignani V, Santini L, Savino S, Granoff DM, Caugant DA, Pizza M, Rappuoli R, Mora M. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J. Exp. Med. 195:1445-1454. (Pubitemid 34602821)
89. Bennett JS, Thompson EA, Kriz P, Jolley KA, Maiden MC, Bennett JS, Thompson EAL, Kriz P, Jolley KA, Maiden MCJ. 2009. A common gene pool for the Neisseria FetA antigen. Int. J. Med. Microbiol. 299:133-139.
90. Sanders H, Brehony C, Maiden MC, Vipond C, Feavers IM. 2012. The effect of iron availability on transcription of the Neisseria meningitidis fHbp gene varies among clonal complexes. Microbiology 158:869-876.
91. Oriente F, Scarlato V, Delany I. 2010. Expression of factor H binding protein of meningococcus responds to oxygen-limitation through a dedicated FNR-regulated promoter. J. Bacteriol. 192:691-701.
92. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM. 2008. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein. Infect. Immun. 76:4232-4240.
93. Welsch JA, Ram S, Koeberling O, Granoff DM. 2008. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197:1053-1061. (Pubitemid 351590035)
94. Welsch JA, Rossi R, Comanducci M, Granoff DM. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine J. Immunol. 172:5606-5615. (Pubitemid 38542063)
95. Scarselli M, Cantini F, Santini L, Veggi D, Dragonetti S, Donati C, Savino S, Giuliani MM, Comanducci M, Marcello FD, Romagnoli G, Pizza M, Banci L, Rappuoli R. 2009. Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J. Mol. Biol. 386:97-108.
96. Vu DM, Wong TT, Granoff DM. 2011. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 29:1968-1973.
97. Giuntini S, Reason DC, Granoff DM. 2012. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor H binding protein. Infect. Immun. 80:187-194.
98. Beernink PT, LoPasso C, Angiolillo A, Felici F, Granoff D. 2009. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol. Immunol. 46:1647-1653.
99. Madico G, Ngampasutadol J, Gulati S, Vogel U, Rice PA, Ram S. 2007. Factor H binding and function in sialylated pathogenic neisseriae is influenced by gonococcal, but not meningococcal, porin. J. Immunol. 178:4489-4497. (Pubitemid 46492401)
100. Vu DM, Pajon R, Reason DC, Granoff DM. 2012. A broadly cross-reactive monoclonal antibody against an epitope on the N-terminus of meningococcal fHbp. Sci. Rep. 2:341.
101. Seib KL, Serruto D, Oriente F, Delany I, Adu-Bobie J, Veggi D, Arico B, Rappuoli R, Pizza M. 2009. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect. Immun. 77:292-299.
102. Jones A, Georg M, Maudsdotter L, Jonsson A-B. 2009. Endotoxin, capsule, and bacterial attachment contribute to Neisseria meningitidis resistance to the human antimicrobial peptide LL-37. J. Bacteriol. 191:3861-3868.
103. Zhu D, Barniak V, Zhang Y, Green B, Zlotnick G. 2006. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis. Vaccine 24:5420-5425. (Pubitemid 43831373)
104. Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G. 2005. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect. Immun. 73:6838-6845. (Pubitemid 41368851)
105. Pillai S, Howell A, Alexander K, Bentley BE, Jiang H-Q, Ambrose K, Zhu D, Zlotnick G. 2005. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 23:2206-2209. (Pubitemid 40341452)
106. Jacobsson S, Mölling P, Olcén P. 2009. Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis. Vaccine 27:5755-5759.
107. Yazdankhah SP, Caugant DA. 2004. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol. 53:821-832. (Pubitemid 39238387)
108. Ala'aldeen DA, Flint M, Oldfield NJ, Omer SA, McNeil LK, Jiang Q, Murphy E, Giardina PC, Novikova EG, Dodge-Scully IL, Bayliss CD, Turner DP, Neal KR, Hoiseth SK, Jansen KU, Anderson AS. 2010. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 28:7667-7675.
109. Anderson AS. 2009. Development of a factor H binding protein vaccine for broad protection against invasive Neisseria meningitidis serogroup B (MNB) disease, p O026. Abstr. 10th Eur. Meningococci Dis. Soc. Meet., Manchester, United Kingdom.
110. Caugant DA. 2008. Genetics and evolution of Neisseria meningitidis: importance for the epidemiology of meningococcal disease. Infect. Genet. Evol. 8:558-565.
111. Maiden MCJ, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, Caugant DA, Feavers IM, Achtman M, Spratt BG. 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenicmicroorganisms. Proc. Natl. Acad. Sci. U. S. A. 95:3140-3145. (Pubitemid 28135868)
112. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794-2803.
113. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. 2007. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J. Infect. Dis. 195:1472-1479. (Pubitemid 46717465)
114. Hao W, Ma JH, Warren K, Tsang RS, Low DE, Jamieson FB, Alexander DC. 2011. Extensive genomic variation within clonal complexes of Neisseria meningitidis. Genome Biol. Evol. 3:1406-1418.
115. English M, MacLennan JM, Bowen-Morris JM, Deeks J, Boardman M, Brown K, Smith S, Buttery J, Clarke J, Quataert S, Lockhart S, Moxon ER. 2000. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal groupCconjugate vaccine in young British infants. Vaccine 19:1232-1238. (Pubitemid 32008291)
116. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER. 2000. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 283:2795-2801. (Pubitemid 30387823)
117. Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, Gilmet G, Papa T. 2005. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatr. Infect. Dis. J. 24:57-62. (Pubitemid 40353317)
118. Koeberling O, Giuntini S, Seubert A, Granoff DM. 2009. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol. 16:156-162.
119. McNeil LK, Zlotnick G, Camposano E, Logan SM, Novikova EG, Zhao XJ, Anderson AS, Pride MW, Jansen KU. 2011. Development of a meningococcal antigen surface expression (Measure) assay for the phenotypic characterization of fHBP expression by Neisseria meningitidis, p 19-20. Abstr. 11th EMGM Meeting, Ljubljana, Slovenia.
120. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, Muzzi A, Andrews W, Chen J, Santos G, Santini L, Boucher P, Serruto D, Pizza M, Rappuoli R, Giuliani MM. 2010. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl. Acad. Sci. U. S. A. 107:19490-19495.
121. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. 2010. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol. 17:840-847.
122. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE. 2010. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50:184-191.
123. Artenstein MS. 1975. Control of meningococcal meningitis with meningococcal vaccines. Yale J. Biol. Med. 48:197-200.
124. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. 1970. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 282:417-420.
125. Gold R, Artenstein MS. 1971. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull. World Health Organ. 45:279-282.
126. Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE. 2011. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr. Infect. Dis. J. 30:451-455.
127. Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. 2011. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum. Vaccin. 7:646-653.
128. Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, Reynolds G, Ziegler JB, Harris SL, Jones TR, Perez JL. 2012. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr. Infect. Dis. J. 31:1061-1068.
129. Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, Jansen KU, Perez JL. 30 October 2012. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr. Infect. Dis. J. [Epub ahead of print.] doi:10.1097/INF.0b013e31827b0d24.
130. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, Anderson AS, Jones TR, Harris SL, Jansen KU, Perez JL. 24 January 2013. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine [Epub ahead of print.] doi:10.1016/j.vaccine.2013.01.021.
131. Gorringe AR, Pajon R. 2012. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum. Vaccin. Immunother. 8:174-183.
132. Pfizer. 2011, posting date. Study evaluating safety, tolerability, and immunogenicity of meningococcal B vaccine in healthy infants. http://clinicaltrials.gov/ct2/show/NCT00798304?term=NCT00798304&rank=1.
133. Jansen, KU. 2011, posting date. Vaccines and Related Biological Products Advisory Committee meeting presentation: VRBPAC meeting to discuss approaches to licensure of meningococcal serogroup B vaccines. http://www.fda.gov/ AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/ VaccinesandRelatedBiologicalProductsAdvisoryCommittee/ucm251454.htm.
134. Anderson AS, Hao L, Jiang Q, Harris SL, Jones TR, Perez JL, York L, Eiden J, Jansen KU. 2013. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease. Hum. Vaccin. Immunother. 9:471-479.
135. Trotter CL, Maiden MC. 2009. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev. Vaccines 8:851-861.
136. van der Avoort HGAM, Berbers GAM, van Binnendijk RS, Boot HJ, Feltkamp MCW, Friesema IHM, de Greeff SC, Hahné SJM, Kemmeren JM, van der Klis FRM, Kramer MA, van Lier EA, van der Maas NAT, de Melker HE, Mooi FR, Reubsaet F, Schouls LM, De Voer RR. 2010. The National Immunisation Programme in the Netherlands. Developments in 2009. RIVM, National Institute for Public Health and the Environment. http://www.rivm.nl/bibliotheek/rapporten/210021012.pdf.
137. Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. 2012. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum. Vaccin Immunother. 8:888-895.
138. Keiser PB, Miller LB, Biggs-Cicatelli S, Zollinger WD. 2009. Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis. Vaccine 27:6809-6813.
139. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, Bowden RA, Cummings JF, Zollinger WD. 2011. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factorHbinding protein, two PorAs and stabilized OpcA expression. Vaccine 29:1413-1420.
140. Keiser PB, Gibbs BT, Coster TS, Moran EE, Stoddard MB, Labrie JE, 3rd, Schmiel DH, Pinto V, Chen P, Zollinger WD. 2010. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 28:6970-6976.
141. Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly J, Granoff DM. 2011. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor H binding protein in infant rhesus monkeys. Vaccine 29:4728-4734.
142. Brunelli B, Del Tordello E, Palumbo E, Biolchi A, Bambini S, Comanducci M, Muzzi A, Pizza M, Rappuoli R, Donnelly JJ, Giuliani MM, Serruto D. 2011. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1. Vaccine 29:1072-1081.
143. Ruijne N, Lea RA, O'Hallahan J, Oster P, Martin D. 2006. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants. Clin. Vaccine Immunol. 13:797-801.
144. Stokley S, Cohn A, Dorell C, Hariri S, Yankey D, Messonnier N, Wortley PM. 2011. Adolescent vaccination-coverage levels in the United States: 2006-2009. Pediatrics 128:1078-1086.
145. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD. 2003. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31:3497-3500. (Pubitemid 37442184)
146. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596-1599. (Pubitemid 47236692)